Organization: Health Canada
Year: 2024
Month: June
Request Number: A-2023-001277
Request Summary: New Drug Submission (NDS) for avapritinib filed by Blueprint Medicines Corporation was accepted into review by Health Canada in or around November 2023. Provide a non-annotated copy of the most recent Certified Product Information Document (CPID) submitted for the Avapritinib NDS.
Disposition: Disclosed in part
Number of pages: 43